biOasis Technologies Ord Shs V.BTI

Primary Symbol: V.BTI.H Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by jdstoxon Sep 09, 2017 11:38am

210 Views

Post# 26675496

biOasis and Resverlogix Share SAB Member

Many biOasis shareholders are, or have been, Resverlogix shareholders. They might be interested to note that Dr. Jeffrey L. Cummings, whose appointment to the biOasis Scientific Advisory Board was announced on Sept 7, 2017, is also a member of the Resverlogix Neurodegenerative Clinical & Scientific Advisory Board. I would think that his involvement with Resverlogix is related to Resverlogix's interest in Alzheimer's Disease.

jd

Bullboard Posts

Geologica Resource: Polymetallic upside at a depressed price